1. Home
  2. ABLV vs RFL Comparison

ABLV vs RFL Comparison

Compare ABLV & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABLV

Able View Global Inc.

N/A

Current Price

$2.28

Market Cap

121.5M

Sector

N/A

ML Signal

N/A

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

N/A

Current Price

$1.08

Market Cap

133.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ABLV
RFL
Founded
2015
2017
Country
China
United States
Employees
164
N/A
Industry
Real Estate
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
121.5M
133.1M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
ABLV
RFL
Price
$2.28
$1.08
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 110.3K
53.3K
Earning Date
12-19-2026
12-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 44.23
EPS
★ N/A
N/A
Revenue
N/A
★ $917,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.70
★ N/A
Revenue Growth
N/A
★ 43.96
52 Week Low
$0.54
$0.99
52 Week High
$2.96
$3.96

Technical Indicators

Market Signals
Indicator
ABLV
RFL
Relative Strength Index (RSI) 51.34 36.06
Support Level $0.75 $0.99
Resistance Level $2.91 $1.38
Average True Range (ATR) 0.38 0.11
MACD -0.06 0.02
Stochastic Oscillator 39.41 25.78

Price Performance

Historical Comparison
ABLV
RFL

About ABLV Able View Global Inc.

Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: